Stockscreener 앱 받기
7.38
3.07%
0.22
시간 외 거래:
7.35
-0.03
-0.41%
전일 마감가:
$7.16
열려 있는:
$7.12
하루 거래량:
108.46K
Relative Volume:
0.98
시가총액:
$47.62M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.5918
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
-1.60%
1개월 성능:
+43.02%
6개월 성능:
-33.03%
1년 성능:
+28.35%
1일 변동 폭
$7.0502
$7.71
1주일 범위
$6.9641
$7.95
52주 변동 폭
$2.92
$11.20
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
KALA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
7.38 | 47.23M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
Trend analysis for KALA BIO Inc. this weekWeekly Trend Watch with Market Signals - Newser
Technical analysis overview for KALA BIO Inc. stockDaily Entry Opportunity Forecasting Tool - Newser
Can volume confirm reversal in KALA BIO Inc.Free Confirmed Setup With Expert Accuracy - Newser
Using portfolio simulators with KALA BIO Inc. includedSmart Risk Entry Zone Technical Analysis - Newser
How KALA BIO Inc. stock performs during market volatilityAccurate Forecast System with AI Support - Newser
Why KALA BIO Inc. stock attracts strong analyst attentionFree Beginner Friendly Stock Selection Guide - Newser
What drives KALA BIO Inc.’s stock priceStocks with 300% Upside - sisaissue.com
KALA BIO Inc. stock trend forecastEntry Opportunity Screener with Confirmation - Newser
Comparing KALA BIO Inc. in custom built stock radarsWatchlist Generator With Real-Time Entry - Newser
KALA BIO: Q2 Earnings Snapshot - Greenwich Time
KALA BIO (NASDAQ:KALA) Stock Rating Lowered by Wall Street Zen - Defense World
Is KALA BIO Inc. a Top Dividend Stock to Watch in 2025Free Value Investing Picks With Stability - Newser
Can KALA BIO Inc. recover in the next quarterFree Community Entry Consensus Trade Ideas - Newser
Momentum divergence signals in KALA BIO Inc. chartShort-Term Profit Alert With Entry Forecast - Newser
Kala Bio (KALA) Q2 Loss Widens 15% - AOL.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Biotech's Long Game: Assessing KALA BIO's Q2 Loss in the Context of Strategic Innovation - AInvest
Kala Bio (KALA) Q2 Loss Widens 15% - The Motley Fool
KALA BIO, Inc. Completes Patient Enrollment in Phase 2b CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect, Reports Financial Results and Upcoming Milestones - Quiver Quantitative
KALA BIO, Inc. SEC 10-Q Report - TradingView
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | KALA Stock News - GuruFocus
KALA BIO, Inc. to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 - Quiver Quantitative
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
What makes KALA BIO Inc. stock price move sharplyFree Short Term Trading Opportunity Watch - Newser
What candlestick patterns are forming on KALA BIO Inc.Machine Learning Stock Price Forecast Tool - Newser
KALA BIO Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDownside Risk Evaluation and Stock Analysis - Newser
What is the dividend policy of KALA BIO Inc. stockUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell KALA BIO Inc. stock in 2025Capitalize on strategic market trends - Jammu Links News
How volatile is KALA BIO Inc. stock compared to the marketRapid growth opportunities - Jammu Links News
Is KALA BIO Inc. stock overvalued or undervaluedAchieve consistent double-digit growth rates - Jammu Links News
What institutional investors are buying KALA BIO Inc. stockCapitalize on proven investment strategies - Jammu Links News
How does KALA BIO Inc. compare to its industry peersOutstanding capital returns - Jammu Links News
Is KALA BIO Inc. a growth stock or a value stockAchieve exceptional returns with expert guidance - Jammu Links News
What is the risk reward ratio of investing in KALA BIO Inc. stockGet professional guidance for market timing - Jammu Links News
Is it the right time to buy KALA BIO Inc. stockFree Stock Market Trend Analysis - Jammu Links News
Why is KALA BIO Inc. stock attracting strong analyst attentionInvest confidently with daily market forecasts - Jammu Links News
Is KALA BIO Inc. a good long term investmentFree Stock Market Trend Analysis - Jammu Links News
What is KALA BIO Inc. company’s growth strategyInvest confidently with professional market insights - Jammu Links News
When is KALA BIO Inc. stock expected to show significant growthGet alerts on high-potential stock breakouts - Jammu Links News
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):